Aptorum Group(APM) - 2023 Q4 - Annual Report

Exhibit 99.1 Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group" or "We"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided an update on corporate developments. Mr. Ian Huen, Chief Executive Officer and Executive Director of Apt ...